# US 2012/0253470 A1 · Compositions for bone tissue repair and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253470 A1
- Document ID: US20120253470A1
- Status: Published application
- Kind: A1
- Application number: 13/435,259
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Assignees: President and Fellows of Harvard College
- Inventors: Kevin A. Guze; Vinicius Souza Rodrigues
- Web page: https://patentgrep.com/patent/US20120253470A1

## CPC

- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/365: {Bones}
- A61L 27/446: {with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61F 2002/2835: {Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material}
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61L 2300/622: Microcapsules
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The technology described herein relates to compositions for promoting bone growth or regeneration. The compositions described herein can comprise bioactive agents and scaffold materials.

## Claims

### Claim 1

A composition for promoting bone growth or bone regeneration comprising at least one bioactive agent, a first scaffold material, and at least one other scaffold material.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the at least one bioactive agent is an agent that promotes angiogenesis or an agent that promotes bone growth.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the at least one bioactive agent is selected from the group consisting of:
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF); prominin-1 peptide (peptide #237); bone morphogenetic protein 2 (BMP2); bone morphogenic protein 4 (BMP4); and bone morphogenic protein 7 (BMP7).

### Claim 4 (depends on 1)

The composition of claim 1, wherein the first scaffold material is bone fragments or bone-derived fragments.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the at least one other scaffold material is selected from the group consisting of:
glycosaminoglycan, silk, fibrin, MATRIGEL™, poly-ethyleneglycol (PEG), polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly(N-vinyl pyrolidone), poly glycolic acid (PGA), poly lactic-co-glycolic acid (PLGA), poly e-carpolactone (PCL), polyethylene oxide, poly propylene fumarate (PPF), poly acrylic acid (PAA), hydrolysed polyacrylonitrile, polymethacrylic acid, polyethylene amine, alginic acid, pectinic acid, carboxy methyl cellulose, hyaluronic acid, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, collagen, gelatin, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, and cationic starch as well as salts and esters thereof.

### Claim 6 (depends on 1)

The composition of claim 1, comprising PLGA, peptide #237 (prom-1 #237), demineralized bone particles and optionally, VEGF and/or PDGF.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the at least one bioactive agent, the first scaffold material, and the at least one other scaffold material are solidified together into a fabricated structure having a defined shape and size.

### Claim 8 (depends on 7)

The composition of claim 7, further comprising a solidifying agent.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the solidifying agent is alginate.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the solidified fabricated structure is porous.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the at least one other scaffold material forms a microsphere.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the microsphere comprises the at least one bioactive agent.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the microsphere is a PLGA microsphere.

### Claim 14 (depends on 13)

The composition of claim 13, comprising a PLGA microsphere, peptide #237 (prom-1 #237), demineralized bone particles, and optionally, VEGF and/or PDGF.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the PLGA microsphere encapsulates PDGF and is coated with VEGF externally.

### Claim 16 (depends on 1)

A method of treating or repairing a hard tissue defect or an oral tissue defect in a subject comprising contacting the defect with a composition of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, further comprising selecting a subject having a hard tissue or oral tissue defect.

### Claim 18 (depends on 16)

The method of claim 16, wherein the defect is selected from the group consisting of:
long bone defects; alveolar bone defects; cranial bone defects; facial bone defects; short bone defects; flat bone defects; irregular bone defects; sesamoid bone defects; cartilage defects; dentoalveolar defects; connective tissue defects; and collagen membrane defects.

### Claim 19 (depends on 16)

The method of claim 16, wherein the composition is used during guided bone regeneration, connective tissue grafts, or sinus lift procedures.

### Claim 20 (depends on 16)

The method of claim 16, wherein the composition is applied to a surgical implant or tissue graft which is implanted into the hard tissue or oral tissue of the subject.
